Microsoft word - msg final release for 4-7-11 distribution.docx
FOR IMMEDIATE RELEASE T2 Biosystems Demonstrates First-Ever Ability to Accurately and Rapidly Detect Systemic Candida Infection Directly in Whole Blood in Single-Process Test
Data Presented at Annual Meeting of Mycoses Study Group Demonstrates Rapid Identification of the Most Deadly Form of Common Hospital-‐Acquired Infections
Magnetic Biosensor Nanotechnology Enables Universal Detection of Targets on Single Platform
Lexington, MA (April 7, 2011) – T2 Biosystems, Inc., a company developing next-
generation diagnostic products, presented data today on the rapid and sensitive detection
of five species of the fungal infection Candida at the Annual Meeting of the Mycoses
The data demonstrate the ability of T2 Biosystems’ proprietary technology platform to
detect Candida organisms in whole blood samples in less than two hours from sample to
result, with very high sensitivity, specificity and accuracy. This initial data supports the
capability for T2 Biosystems’ technology to provide significant clinical advantages in
time, healthcare cost and associated patient mortality when compared to the currently
available multiple-day diagnosis of Candida from blood culture. The system utilizes
magnetic biosensor nanotechnology that is designed to enable detection of DNA, RNA,
protein, small molecules and a number of other targets from a single sample and single
platform. The company plans to submit the diagnostic device, including the Candida
application, for clearance by the U.S. Food and Drug Administration in 2012.
Candidemia, a systemic fungal infection that occurs when Candida organisms are present
in the blood, is a potentially life-threatening bloodstream infection. Each year, an
estimated 60,000 patients contract candidemia in the United States alone, and this
incidence continues to rise. It is the most deadly of the common hospital-acquired
bloodstream infections, and currently results in significant increased hospital stays,
“The current standard of care in Candida detection involves analyzing biological samples
using culture-based methods that typically take several days to produce a result. During
this time, patients are often treated with broad spectrum antibiotics, which introduce
additional complications to exacerbate the infection and can lead to significant morbidity
and mortality,” said Peter Pappas, MD, Principal Investigator of the Mycoses Study
Group. “If we rely on current post-culture diagnostic techniques, roughly 40% of patients
suffering from candidemia will not survive. This underscores the need for rapid and
accurate diagnostics to ensure early and appropriate therapy that can save patient lives.”
The T2 Biosystems data presented at the Mycoses Study Group meeting includes an
evaluation of more than 400 human whole blood samples spiked with clinical isolates and
lab strains for Candida albicans, Candida krusei, Candida glabrata, Candida tropicalis,
and Candida parapsilosis. The tests demonstrate that the T2 Biosystems method was able
to detect all five species of Candida in whole blood, pre-culture samples with 95%
sensitivity and 98% specificity. Additionally, greater than 98% positive agreement with
blood culture was demonstrated for over 160 spiked patient samples with clinical isolates
and lab strains. These results were reproducible across different days and different patient
“The results from our tests to detect Candida in whole blood samples in less than two
hours are unprecedented and represent a major breakthrough for this deadly fungal
infection,” said John McDonough, Chief Executive Officer of T2 Biosystems. “This is a
terrific example of how T2 Biosystems’ technology removes the sample preparation
barriers of existing diagnostics to improve patient outcomes by enabling rapid detection
directly in whole blood samples for the most challenging diagnostic tests.”
T2 Biosystems’ magnetic biosensor nanotechnology has been applied to the sensitive
detection of a broad range of analytes, including viruses, bacteria, proteins, hormones,
DNA, RNA, small molecules and other diagnostic targets, and has been published in over
100 journal articles. The company is developing a pipeline of diagnostic products based
About T2’s Magnetic Biosensor Technology
Unlike culture based diagnostic methods that utilize optical signals and require
preparation of a clean biologic sample, T2’s magnetic biosensor technology combines
nanotechnology with the power of magnetic resonance detection. A “dirty sample” of a
patient’s blood, saliva, urine or other biofluid is loaded directly into a desktop instrument
via a disposable cartridge. The sample is then mixed with magnetic nanoparticles and
analyzed for the presence of specific fungal, bacterial or viral pathogens or biomarkers
using a technique similar to magnetic resonance imaging (MRI). The system is able to
detect low concentrations of target agents or specific pathogens and present a result to the
About Candida Infections
Candidemia is a systemic fungal infection that occurs when Candida organisms in the
blood spread to organs and tissues throughout the body. An estimated 60,000 patients
contract candidemia in the United States each year.1 While not all cases are hospital
acquired, it is the most deadly of the common hospital acquired infections, with a
mortality rate of 40% compared to 27% mortality for hospital acquired infections in
general.2,3 In the absence of a rapid, accurate diagnostic, appropriate therapeutic
intervention for candidemia is often delayed, resulting in a mortality rate that is three to
four times higher than when early, targeted therapy is initiated.4,5 Patients at high risk for
candidemia and systemic Candida infection include those with compromised immune
systems, transplant recipients, patients on chemotherapy, patients with catheters, patients
in critical care units, surgical patients and patients on prolonged antibiotic therapy.
Candidemia contributes to an average of 23 additional days in the hospital per patient6
and experts estimate that patients who suffer from candidemia cost the U.S. healthcare
About T2 Biosystems, Inc.
T2 Biosystems is a private biomedical company developing next-generation medical
diagnostic products using its proprietary NanoDx™ magnetic biosensor technology
platforms to provide rapid, accurate and scalable diagnostics for both centralized and
decentralized clinical settings. T2 Biosystems was founded in 2006 by renowned
researchers from the Massachusetts Institute of Technology, Harvard University, Harvard
Medical School and Massachusetts General Hospital, and has assembled a world class
team, board of directors and scientific advisory board that collectively have a proven
track record of translating technologic innovations into breakthrough products, building
significant corporate value. T2 Biosystems is located in Lexington, Massachusetts. For
more information, please visit the company's website at www.t2biosystems.com.
1. Data on file - Mycology from the perspective of the Clinician, Wingard JR.
2. Pfaller MA, Diekema DJ. Epidemiology of Invasive Candidiasis: a Persistent
Public Health Problem. Clinical Microbiology Reviews, 2007; 20 (1): 133–163.
3. Edmond MB, Wallace, SE, McClish DK, et al. Nosocomial Bloodstream
Infections in United States Hospitals: A Three-Year Analysis. Clinical Infectious Diseases, 1999; 29: 239–44.
4. Morrell M, Fraser VJ, Kollef MH. Delaying the Empiric Treatment of Candida
Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality. Antimicrobial Agents And Chemotherapy, 2005; 49(9): 3640–3645.
5. Garey KW, Rege M, Pai MP, et al. Time to Initiation of Fluconazole Therapy
Impacts Mortality in Patients with Candidemia: A Multi-Institutional Study. Clinical Infectious Diseases 2006; 43:25–31.
6. Gagne JJ, Breitbart RE, Maio V, et al., Costs Associated with Candidemia in a
Hospital Setting. P&T 2006; 31(10) 586-619.
7. Wilson LS, Reyes CM, Stolpman M, et al. The Direct Cost and Incidence of
Systemic Fungal Infections. Value in Health 2002 ; 5(1).
Kathryn Morris The Yates Network Tel: 845-635-9828 [email protected]
Prozac - Bekenntnisse eines Pharma-Täters Zehn Jahre lang ging's immer nur aufwärts für John Virapen. In Schweden machte er beim Pharma-Riesen Eli Lilly grosse Karriere. Dann wurde er von einem Tag auf den anderen abgesägt. Heute blickt er schuldbewusst und reuevoll auf das zurück, bei dem er Komplize war, und was er in einem spektakulären Bekenntnis-Buch veröffentlicht hat: "
Medizinisches Onlinemagazin Personalisiert und einzigartig auf der Welt. Jetzt ganz neu im Internet, auch auf ihrem Browser zu sehen! Gehen Sie einfach nur auf Das weltweit erste personalisierte Online-Magazin DAS WELTWEIT ERSTE PERSONALISIERTE ONLINE-MAGAZINMit Diabetes im Kindergarten - ein Problem?Im Kindergarten können die Jüngsten nach Herzens-gepackt werden. Um Probleme so w